Início › Câncer de Fígado (Carcinoma Hepatocelular) › Illinois
Ensaios clínicos de Câncer de Fígado (Carcinoma Hepatocelular) em Illinois
20 estudos para Câncer de Fígado (Carcinoma Hepatocelular) estão buscando participantes em locais em Illinois.
Cidades em Illinois
Texto oficial do estudo (Inglês)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07227012National Liver Cancer Screening Trial
- Northwestern University, Chicago
RecrutandoFase 4
Idades de 18 a 85 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06084234A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0107, Chicago
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07291076Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- OSF St. Francis Medical Center, Peoria
RecrutandoFase 2
Idades de 18 a 100 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07219459A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- City of Hope Chicago Cancer Center, Zion
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06427941Defining the Ablative Dose for Y-90 TARE
- Northwestern University, Chicago
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT07586046Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
RecrutandoEstudo observacional
Idades 22 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT06486454Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Chicago
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
RecrutandoFase 1/2
12 Months – 30 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- e mais 6
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT07166406A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06330064Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle Cancer Center NCI Community Oncology Research Program, Urbana
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05168163DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Rush University Medical Center, Chicago
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 21 de jul. de 2026 · NCT07717437Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
- Northwestern University, Chicago
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de jun. de 2026 · NCT07042919A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Chicago
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 17 de jun. de 2026 · NCT06600321Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
- Northwestern University, Chicago
- Northwestern Medicine Kishwaukee Hospital, DeKalb
- Northwestern Medicine Delnor Hospital, Geneva
- e mais 4
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 26 de mai. de 2026 · NCT05620771Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- University of Chicago Medical Center, Chicago
- Methodist Medical Center of Illinois, Peoria
RecrutandoFase 4
Idades de 18 a 64 · Todos os sexos · Atualizado em 22 de jan. de 2026 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Rush University Medical Center, Chicago
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 15 de mai. de 2025 · NCT06914648Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.